Crescent Biopharma earnings were -$165.1M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest CBIO earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$24.8M, up 6.7% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, CBIO reported annual earnings of -$153.9M, with 306.4% growth. The next CBIO earnings date is Nov 5, 2026.
What were Crescent Biopharma's earnings last quarter?
On CBIO's earnings call on Jul 30, 2026, Crescent Biopharma (NASDAQ: CBIO) reported Q2 2026 earnings per share (EPS) of -$0.74, up 84.99% year over year. Total CBIO earnings for the quarter were -$24.84 million. In the same quarter last year, Crescent Biopharma's earnings per share (EPS) was -$4.93.
The next CBIO earnings call is Nov 5, 2026. Add CBIO to your watchlist to be reminded of Crescent Biopharma's next earnings date.
Is Crescent Biopharma profitable or losing money?
As of the last Crescent Biopharma earnings report, Crescent Biopharma is currently losing money. Crescent Biopharma's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$165.12 million, a 155.49% increase year over year.
What was CBIO's earnings growth in the past year?
As of Crescent Biopharma's earnings date in Jul 30, 2026, Crescent Biopharma's earnings has grown year over year. CBIO earnings in the past year totalled -$165.12 million.
What are Crescent Biopharma's earnings expectations?
The current EPS estimate for Crescent Biopharma's earnings report in Nov 5, 2026 is -$0.71.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.